A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

NCT02730208 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: Tezacaftor/Ivacaftor
DRUG: Ivacaftor
DRUG: Placebo
DRUG: Placebo

Sponsor

Vertex Pharmaceuticals Incorporated